Greg Smith

Greg Smith serves as a key procurement professional within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, supporting the agency’s mission to secure and deploy medical countermeasures against public health emergencies. He manages the acquisition lifecycle for critical biodefense capabilities, including vaccines, therapeutics, and advanced manufacturing platforms, ensuring rapid responsiveness to emerging threats. His work centers on high-stakes, time-sensitive contracts aligned with national preparedness priorities, often involving complex regulatory pathways and advanced biotechnology development. Smith maintains consistent contracting relationships with specialized biopharmaceutical innovators, including Cidara Therapeutics, Aquestive Therapeutics, Rafah Laboratories, and Osivax. These partnerships reflect a focus on firms with expertise in novel antiviral formulations, drug delivery systems, and platform-based vaccine technologies. His procurement approach prioritizes technical capability and scalability over socioeconomic preferences, with all awards issued under full and open competition without set-asides, indicating a deliberate emphasis on mission-critical speed and access to cutting-edge capabilities. His contracting activity is concentrated in two primary NAICS categories: Biological Product (except Diagnostic) Manufacturing (325414) and Research and Development in Biotechnology (541714). This reflects a deep specialization in procuring preclinical and clinical-stage biologics, biosafety-compliant manufacturing services, and advanced R&D for next-generation medical countermeasures. Smith’s portfolio demonstrates technical fluency in mRNA, viral vector, and recombinant protein platforms, with a consistent focus on accelerating transition from lab to large-scale production to meet urgent public health needs.